VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Email reply from McWhirter

<< Previous

Bullboard Posts

Next >>

Comment by leonenoelon May 14, 2021 4:51am

325 Views

Post# 33201663

RE:RE:RE:RE:RE:RE:RE:Email reply from McWhirter

Invitations were emailed to people who signed up for newsletters. Interview was yesterday at noon and lasted 2 hours. Big turnout according the host, Dr. Swain.

Dr. Adams introduced a new patent for a fully operational 4D complete mathematical measurement of all heart functions with no peer anywhere in the world.
Increased 3D measurement functionality.
Fully automated AI software works (no more clicking to match data points). Now fine-tuning it.
Successfully integrated into GE ultrasound machines. GE now testing it.
Training GE expected to require very little time.
Additionally functionality but not revealing what it is yet (probably due to pending patents).
Institutional funds taking positions in the stock. 6 US banks approached Dr. Adams to raise funds.
$4 million cash in the bank, no funds needed for 3 years.
Significant revenues expected in 3 to 6 months.
Uplisting to Nasdaq.
Next BioPub maybe next month.